Status:
WITHDRAWN
Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea
Lead Sponsor:
The University of Texas Health Science Center, Houston
Conditions:
Travelers' Diarrhea
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The study will compare durations of diarrhea among subjects who report to clinic for treatment and who receive either: 1. standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, ...
Eligibility Criteria
Inclusion
- passage of 3 or more unformed stools in 24 hours plus an additional symptom of enteric disease such as abdominal cramps, nausea, vomiting, or fever; and investigator verification that an unformed stool has been submitted.
- is \> 18 years of age
- has diarrhea (at least three unformed stools in 24 hrs) plus at least one additional sign or symptom of enteric illness
- has acute diarrhea less than 1 week's duration
- willingness to provide a diarrhea stool sample
- willingness to keep a daily diary for 5 days
- signed informed consent
Exclusion
- fever or bloody diarrhea
- has taken predictably effective antibiotics in the past week (e.g. quinolones, TMP/SMX, azalide or doxycycline)
- is pregnant now, likely to become pregnant, or breast-feeding
- has duration of diarrhea of greater than 1 weeks
- is allergic to Rifampin or Rifaximin
- has a history of significant underlying enteric, pulmonary, cardiac, renal disease, or any CNS disorder
- is more than moderately dehydrated
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00875875
Start Date
June 1 2009
End Date
June 1 2009
Last Update
June 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Enteric Disease Clinic
Guadalajara, Jalisco, Mexico